Geilfuss, Faget Comment on Implications of Possible ACA Ruling
December 19, 2018
Modern Healthcare
Partner Fred Geilfuss and Special Counsel Kyle Faget were quoted in a Modern Healthcare article, “ACA repeal wouldn’t stop transition to value-based payment, efforts to lower drug spending,” about what would happen if the Affordable Care Act is ultimately held to be unconstitutional.
Geilfuss said providers that have already invested in the infrastructure, technology and staff to facilitate new payment models like accountable care organizations, bundled payments and Medicare Shared Savings would probably continue to do so. “To just throw that out seems very unlikely,” he said. “There would be a lot of people who are motivated to figure out a way to continue that momentum.”
Faget said if the ACA is found to be unconstitutional, Congress would probably reenact the Biologics Price Competition and Innovation Act of 2009, which was folded into the ACA, as a standalone law. The act allows the Food and Drug Administration to approve biosimilars, which mimic expensive biologic drugs made from living organisms. “Biosimilars are absolutely a big part of reducing drug prices,” she said.
Geilfuss said providers that have already invested in the infrastructure, technology and staff to facilitate new payment models like accountable care organizations, bundled payments and Medicare Shared Savings would probably continue to do so. “To just throw that out seems very unlikely,” he said. “There would be a lot of people who are motivated to figure out a way to continue that momentum.”
Faget said if the ACA is found to be unconstitutional, Congress would probably reenact the Biologics Price Competition and Innovation Act of 2009, which was folded into the ACA, as a standalone law. The act allows the Food and Drug Administration to approve biosimilars, which mimic expensive biologic drugs made from living organisms. “Biosimilars are absolutely a big part of reducing drug prices,” she said.
People
Related News
July 11, 2025
In the News
Foley Attorneys Assess Critical IP Considerations for Emerging Medical Device Companies
Foley & Lardner LLP attorneys Shabbi Khan, Nate Beaver, Austin Kim, and Jeff Simon authored the Med Device Online article, "Critical Considerations For IP & Patents For Emerging Medical Device Companies."
July 11, 2025
In the News
David Morris Featured for Arrival to Foley's Salt Lake City Office
Foley & Lardner LLP partner David Morris is highlighted across legal press for his recent arrival to the firm.
July 10, 2025
In the News
Ann Marie Uetz Comments on Automotive Supply Chain Approach to Evolving Tariff Environment
Foley & Lardner LLP partner Ann Marie Uetz shared perspective from the automotive supply chain amid the evolving trade environment in the Crain's Detroit article, "Ford, Stellantis tighten terms on suppliers as tariff costs add up."